130 F. J. Swartling models of Parkinson disease. Neuropathology. 2006;26: 129–40. 76. Villa A, Snyder EY, Vescovi A, Martinez-Serrano A. Estab- lishment and properties of a growth factor-dependent, perpetual neural stem cell line from the human CNS. Exp Neurol. 2000;161:67–84. 77. Queva C, Hurlin PJ, Foley KP, Eisenman RN. Sequential expression of the MAD family of transcriptional repressors during differentiation and development. Oncogene. 1998; 16:967–77. 78. Schreiber-Agus N, DePinho RA. Repression by the Mad (Mxi1)-Sin3 complex. Bioessays. 1998;20:808–18. 79. Wechsler DS, Shelly CA, Petroff CA, Dang CV. MXI1, a putative tumor suppressor gene, suppresses growth of human glioblastoma cells. Cancer Res. 1997;57:4905–12. 80. Manni I, Tunici P, Cirenei N, Albarosa R, Colombo BM, Roz L, et al. Mxi1 inhibits the proliferation of U87 glioma cells through down-regulation of cyclin B1 gene expression. Br J Cancer. 2002;86:477–84. 81. Hann SR, Eisenman RN. Proteins encoded by the human c-myc oncogene: differential expression in neoplastic cells. Mol Cell Biol. 1984;4:2486–97. 82. Pulverer BJ, Fisher C, Vousden K, Littlewood T, Evan G, Woodgett JR. Site-speciﬁc modulation of c-Myc cotransfor- mation by residues phosphorylated in vivo. Oncogene. 1994; 9:59–70. 83. Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev. 2000;14:2501–14. 84. Gregory MA, Qi Y, Hann SR. Phosphorylation by glycogen synthase kinase-3 controls c-myc proteolysis and subnuclear localization. J Biol Chem. 2003;278:51606–12. 85. Flinn EM, Busch CM, Wright AP. Myc boxes, which are conserved in myc family proteins, are signals for protein degradation via the proteasome. Mol Cell Biol. 1998;18: 5961–9. 86. Salghetti SE, Kim SY, Tansey WP. Destruction of Myc by ubiquitin-mediated proteolysis: cancer-associated and trans- forming mutations stabilize Myc. EMBO J. 1999;18:717–26. 87. Yeh E, Cunningham M, Arnold H, Chasse D, Monteith T, Ivaldi G, et al. A signalling pathway controlling c-Myc deg- radation that impacts oncogenic transformation of human cells. Nat Cell Biol. 2004;6:308–18. 88. Schrader EK, Harstad KG, Matouschek A. Targeting proteins for degradation. Nat Chem Biol. 2009;5:815–22. 88. Thrower JS, Hoffman L, Rechsteiner M, Pickart CM. Recog- nition of the polyubiquitin proteolytic signal. EMBO J. 2000; 19:94–102. 90. Blancato J, Singh B, Liu A, Liao DJ, Dickson RB. Correlation of ampliﬁcation and overexpression of the c-myc oncogene in high-grade breast cancer: FISH, in situ hybridisation and immunohistochemical analyses. Br J Cancer. 2004;90: 1612–19. 91. Pollack JR, Sorlie T, Perou CM, Rees CA, Jeffrey SS, Lonning PE, et al. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci USA. 2002;99:12963–8. 92. Vita M, Henriksson M. The Myc oncoprotein as a therapeutic target for human cancer. Semin Cancer Biol. 2006;16: 318–30. 93. Thomas LR, Tansey WP. Proteolytic control of the onco- protein transcription factor Myc. Adv Cancer Res. 2011;110: 77–106. 94. Yada M, Hatakeyama S, Kamura T, Nishiyama M, Tsunematsu R, Imaki H, et al. Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. EMBO J. 2004;23:2116–25. 95. O’Neil J, Look AT. Mechanisms of transcription factor dereg- ulation in lymphoid cell transformation. Oncogene. 2007;26: 6838–49. 96. Hoeck JD, Jandke A, Blake SM, Nye E, Spencer-Dene B, Brandner S, et al. Fbw7 controls neural stem cell differenti- ation and progenitor apoptosis via Notch and c-Jun. Nat Neurosci. 2010;13:1365–72. 97. Jandke A, Da Costa C, Sancho R, Nye E, Spencer-Dene B, Behrens A. The F-box protein Fbw7 is required for cerebellar development. Dev Biol. 2011;358:201–12. 98. Kim SY, Herbst A, Tworkowski KA, Salghetti SE, Tansey WP. Skp2 regulates Myc protein stability and activity. Mol Cell. 2003;11:1177–88. 99. Gstaiger M, Jordan R, Lim M, Catzavelos C, Mestan J, Slingerland J, et al. Skp2 is oncogenic and overexpressed in human cancers. Proc Natl Acad Sci USA. 2001;98:5043–8. 100. von der Lehr N, Johansson S, Wu S, Bahram F, Castell A, Cetinkaya C, et al. The F-box protein Skp2 participates in c-Myc proteosomal degradation and acts as a cofactor for c-Myc-regulated transcription. Mol Cell. 2003;11:1189–200. 101. Popov N, Wanzel M, Madiredjo M, Zhang D, Beijersbergen R, Bernards R, et al. The ubiquitin-speciﬁc protease USP28 is required for MYC stability. Nat Cell Biol. 2007;9:765–74. 102. Schwamborn JC, Berezikov E, Knoblich JA. The TRIM- NHL protein TRIM32 activates microRNAs and prevents self-renewal in mouse neural progenitors. Cell. 2009;136: 913–25. 103. Papas TS, Lautenberger JA. Sequence curiosity in v-myc oncogene. Nature. 1985;318:237. 104. Hoang AT, Lutterbach B, Lewis BC, Yano T, Chou TY, Barrett JF, et al. A link between increased transforming activity of lymphoma-derived MYC mutant alleles, their defective regulation by p107, and altered phosphorylation of the c-Myc transactivation domain. Mol Cell Biol. 1995;15: 4031–42. 105. Bamford S, Dawson E, Forbes S, Clements J, Pettett R, Dogan A, et al. The COSMIC (Catalogue of Somatic Muta- tions in Cancer) database and website. Br J Cancer. 2004;91: 355–8. 106. Land H, Parada LF, Weinberg RA. Tumorigenic conversion of primary embryo ﬁbroblasts requires at least two cooperat- ing oncogenes. Nature. 1983;304:596–602. 107. Foroni C, Galli R, Cipelletti B, Caumo A, Alberti S, Fiocco R, et al. Resilience to transformation and inherent genetic and functional stability of adult neural stem cells ex vivo. Cancer Res. 2007;67:3725–33. 108. Forbes SA, Bhamra G, Bamford S, Dawson E, Kok C, Clements J, et al. The Catalogue of Somatic Mutations in Cancer (COSMIC). Curr Protoc Hum Genet. 2008;Chapter 10:Unit 10.11. 109. Hydbring P, Bahram F, Su Y, Tronnersjo S, Hogstrand K, von der Lehr N, et al. Phosphorylation by Cdk2 is required for Myc to repress Ras-induced senescence in cotransforma- tion. Proc Natl Acad Sci USA. 2010;107:58–63. 110. Campaner S, Doni M, Hydbring P, Verrecchia A, Bianchi L, Sardella D, et al. Cdk2 suppresses cellular senescence induced by the c-myc oncogene. Nat Cell Biol. 2010;12: 54–9; sup pp 1–14. 111. Johansson FK, Brodd J, Eklof C, Ferletta M, Hesselager G, Tiger CF, et al. Identiﬁcation of candidate cancer-causing